Ionis Insiders Sold at $85, Then Bought at $52
Goldman Sachs raised its Ionis Pharmaceuticals price target today, lifting shares 4% in after-hours trading, yet the stock sits roughly 28% below the $79 to $85 range where three insiders sold $3.5M t
Ionis Insiders Sold at $85, Then Bought at $52
NEW YORK, August 20 —
Ionis Pharmaceuticals, Inc. (IONS) received a Goldman Sachs price target increase today and rallied 4% in after-hours trading, yet the stock sits roughly 28% below the prices at which the company's Chief Scientific Officer and two directors sold nearly $3.5M in shares in early July, three weeks before a surprise trial failure crashed the stock 23%.
- Trailing revenue fell 40.7% year-over-year to $870M; gross margin is negative 6.9%; trailing EPS is negative $3.55.
- Three insiders sold ~$3.5M at $79, $85 between July 1-7; Director Hayden bought 20,000 shares at $51, $53 on July 30-31.
- IONS trades at $60.80 against a $89.33 consensus price target; short interest is 17.1% of float.
Bennett's Open-Market Sales Lack the Easy Explanation
CSO C. Frank Bennett sold 20,536 shares on July 7, collecting approximately $1.74M at prices of $83.58 and $85.46. That same day, Director Allene M. Diaz exercised options at $47.11 and immediately sold 10,111 shares at $85.42, netting roughly $864,000; Director Klein Joseph III had done similarly a week earlier, selling 11,518 shares at $79.04 to $79.45 on July 1 following option exercises at $39.94. The option-exercise-and-sell structure explains some of it: Diaz and Klein monetized long-dated equity grants at set prices. Bennett's two transactions were pure open-market sales with no option exercise attached, making the timing harder to explain away as routine compensation mechanics.
One Director Buys What Three Sold
Director Michael R. Hayden's response to the crash was direct: on July 30-31, the day after Ionis filed its Q2 2026 earnings 8-K, he purchased 20,000 shares at $53.38 and $51.60, committing approximately $1.06M of his own capital. Ionis makes four commercial RNA-targeted medicines, including SPINRAZA for spinal muscular atrophy and the recently approved TRYNGOLZA for familial chylomicronemia syndrome, and has beaten consensus EPS estimates in each of the last four quarters by margins of 5.8% to 60.6%. Goldman Sachs's target lift today, citing the TRYNGOLZA approval, points the same direction Hayden did three weeks earlier: the crash may have overshot the damage.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| IONS | $10.1B | n/a | +40.6% |
| ALNY | $32.5B | 19.3x | -48.1% |
| SRPT | $2.1B | 7.7x | -1.6% |
| AGIO | $2.1B | n/a | -8.1% |
| INCY | $26.0B | 14.4x | +48.5% |
| BMRN | $13.4B | 10.7x | +19.6% |
The Burn Rate Is the Referee
Operating cash flow burned $496M over the trailing year, and Ionis holds $2.10B in cash against $2.19B in total debt. The DCF calculator can model whether the commercial portfolio closes that gap. Short interest at 17.1% of float reflects that the bears have not conceded. The specific checkpoint is gross margin: if TRYNGOLZA's ramp drives the company's current negative 6.9% margin toward breakeven in the next two quarters, Hayden's post-crash purchase at $52 looks prescient; if the burn holds and Olezarsen's Phase 3 disappoints, the sellers at $85 will have called it correctly. Run the free Ionis Pharmaceuticals, Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Ionis insiders sell before the stock crashed?
Three Ionis insiders sold roughly $3.5M in shares between July 1 and 7 at prices from $79 to $85. Directors Diaz and Klein exercised long-dated options and immediately sold, a structure common in executive compensation plans. CSO C. Frank Bennett's sales were pure open-market transactions with no option exercise attached, making the timing harder to explain as routine compensation mechanics.
What specifically did Ionis CSO C. Frank Bennett sell?
Bennett sold 20,536 shares on July 7 at prices of $83.58 and $85.46, collecting approximately $1.74M in two transactions. Unlike the two directors who sold after option exercises, Bennett's sales had no option grant attached. That distinction is what the article identifies as analytically significant about the pre-crash insider activity.
How much did Director Hayden buy after the crash?
Director Michael R. Hayden purchased 20,000 shares on July 30 and 31 at $53.38 and $51.60, committing approximately $1.06M of his own capital. The purchases came the day after Ionis filed its Q2 2026 earnings 8-K. Goldman Sachs's price target increase today, citing the TRYNGOLZA approval, points in the same direction as Hayden's post-crash buys.
What is Ionis Pharmaceuticals' financial position?
Ionis holds $2.10B in cash against $2.19B in total debt, with operating cash flow burning $496M over the trailing year. Trailing revenue fell 40.7% year-over-year to $870M, gross margin is negative 6.9%, and trailing EPS is negative $3.55. The company has nonetheless beaten consensus EPS estimates in each of the last four quarters by margins ranging from 5.8% to 60.6%.
What is the consensus price target for Ionis stock?
The analyst consensus price target for Ionis is $89.33 against a current price of $60.80. Goldman Sachs raised its target today, citing the TRYNGOLZA approval, and shares rallied 4% in after-hours trading. Short interest stands at 17.1% of float, indicating the bearish position has not been abandoned.
Goldman Sachs raised its price target on Ionis Pharmaceuticals today, triggering a 4% after-hours gain — yet IONS currently trades roughly 28% below the prices at which the company's own Chief Scientific Officer and multiple directors sold nearly $3.5M in shares just six weeks ago, days before a 23% crash on a surprise trial failure.